Compare Merck & Co., Inc. (MRK) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Consumer Staples Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Consumer Staples Select Sector SPDR Fund trades at $83.19. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MRK | XLP | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $90.00 |
52-Week Low | $77.60 | $75.61 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.02, down 0.66% on the day amid broader market volatility. The technical picture shows bearish momentum with selling pressure outweighing buying signals 14 to 6, though oscillators suggest potential stabilization. Analyst consensus remains strongly positive with 100% buy ratings, highlighting XLP's defensive characteristics during economic uncertainty. Recent news emphasizes the fund's appeal as a safe haven with its 2.6% dividend yield and exposure to stable consumer staples companies.
XLP offers defensive exposure to essential consumer goods companies, providing stability during market turbulence. The fund's low 0.08% expense ratio and consistent dividend payments support its appeal for risk-averse investors. However, limited growth potential compared to cyclical sectors and sensitivity to consumer spending trends present ongoing challenges for significant price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
